Register for OBR daily


GH_edutorial_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

BMRN $128.78 13.2300 +11.45%
CALA $17.45 1.5700 +9.89%
VICL $0.92 0.0677 +7.92%
MRTX $28.42 2.0500 +7.77%
NLNK $52.26 3.3300 +6.81%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

OHRP $2.74 -5.9900 -68.61%
LOXO $12.37 -1.0450 -7.79%
IMDZ $24.09 -1.5600 -6.08%
CNDO $3.58 -0.2200 -5.79%
MEIP $1.74 -0.0900 -4.92%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Targeting Nodal in Combination With Dacarbazine Produces Anticancer Effects in Metastatic Melanoma

(Lurie's Childrens Hospital of Chicago) Mar 12, 2015 - Researchers found that standard treatments for metastatic melanoma are not effective against a growth factor protein called Nodal. The study also showed that combination therapies incorporating anti-Nodal antibodies with Dacarbazine (DTIC) are a promising alternative.
read press release 



New Genome Editing Technology Helps Study and Treat Blood Cancers

(Walter and Eliza Hall Institute [Australia]) Mar 13, 2015 - Melbourne researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.
read press release 



A Genetically Engineered Immunotoxin Shows Early Promise in Patients With B-cell Malignancies

(AACR) Mar 13, 2015 - DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be safe and clinically effective in a small group of patients with relapsed/refractory B-cell malignancies, according to phase I clinical trial data published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
read press release 



UCLA Researchers Develop More Accurate Tool to Predict Whether Liver Cancer Will Recur in Transplant Patients

(UCLA) Mar 12, 2015 - UCLA transplant researchers have developed a novel method to more accurately calculate the risk of disease recurring in people with liver cancer who have undergone a liver transplant.
read press release 



Why a Powerful Cancer Drug Only Helps Some Patients

(Science AAAS) Mar 12, 2015 - Researchers have found a genetic signature within lung tumors that seems to predict whether this immunotherapy drug will work—and who will benefit most.
read article  



NCCN Recommends Only One Genomic Test For Breast Cancer

(Medscape Medical News) Mar 12, 2015 - The National Comprehensive Cancer Network (NCCN) only endorses one genomic test for use in patients with early-stage breast cancer, according to a presenter here at the NCCN 20th Annual Conference.
read article (free registration required) 



Is the Cost of Cancer Care Killing Us?

(Forbes) Mar 13, 2015 - Progress in the war against cancer has come at a steep financial cost. According to experts, cancer care accounted for 5% of US healthcare spending in 2010 to the tune $125 billion.
read article 



Two-Thirds in U.S. With Invasive Cancer Live Five or More Years: Study

(Reuters) Mar 12, 2015 - Two out of three people in the United States with cancer that has spread to nearby tissue live at least five years after they are diagnosed, according to a federal study released on Thursday.
read article 



66% of People Diagnosed with Cancer Survive At Least 5 Years

(Time) Mar 12, 2015 - Two out of three Americans with invasive cancer—the kind that has spread to nearby healthy tissue—are living five years or more after diagnosis, according to a new report from the U.S. Centers for Disease Control and Prevention (CDC).
read article 



Geography Matters: Imaging Overuse Seen for Breast & Prostate Cancer in Certain Regions Across the U.S.

(NYU Langone) Mar 12, 2015 - New study from NYU Langone Medical Center shows over 40 percent of low-risk patients received inappropriate tests.
read press release 



CML Guide: Consider Early TKI Switch in Poor Responders

(Medscape Medical News) Mar 13, 2015 - Give it 3 months, but if a patient with chronic myelogenous leukemia (CML) has a suboptimal response to therapy with a first-line tyrosine kinase inhibitor (TKI), it's not too soon to consider trying a different drug, according to clinical guidelines from the National Comprehensive Cancer Network (NCCN).
read article (free registration required) 



Congress Could Pursue a Permanent Medicare Physician Payment Fix

(California Healthline) Mar 12, 2015 - House and Senate leaders are discussing a permanent fix for Medicare's sustainable growth rate formula, lawmakers and aides said Wednesday, the Wall Street Journal reports (Peterson/Radnofsky, Wall Street Journal, 3/11).
read article 



Acadia Delays Seeking Approval of Parkinson's Drug

(Morningstar/Dow Jones Newswires) Mar 11, 2015 - Acadia Pharmaceuticals won't be seeking regulatory approval for its lead drug candidate to treat Parkinson's disease psychosis until the second half of the year.
read article 



Endo Confirms Bid for Drug Maker Salix, Topping Offer From Valeant

(New York Times/DealBook) Mar 11, 2015 - Endo International, a big drug firm, has thrown a wrench into Valeant Pharmaceuticals’ plans to acquire Salix Pharmaceuticals, a maker of treatments for gastrointestinal disorders.
read article 



Google's Genetic Test Maker 23andMe Launches Drug Development Effort

(CBS SF Bay Area/Associated Press) Mar 12, 2015 - Google-backed genetic testing company 23andMe is launching its own drug development unit, betting that it can translate its database of customer DNA information into novel medicines.
read article 



Results of Many Clinical Trials Not Being Reported

(NPR/Shots blog) Mar 11, 2015 - Many scientists are failing to live up to a 2007 law that requires them to report the results of their clinical trials to a public website, according to a study in Thursday's New England Journal of Medicine.
read article 



Drugmakers Turn Heat on Insurers by Backing Copay Limits

(Bloomberg) Mar 12, 2015 - The battle over soaring U.S. drug prices is heading for the states. With the price of some treatments topping $100,000, patient groups are pushing for state laws to make sure insurers cover most of the costs. Their campaign is backed by an important ally: the drug industry.
read article 



Hackensack University Medical Center Opens New Cancer Treatment Center

(NorthJersey.com/The Record [NJ]) Mar 11, 2015 - Hackensack University Medical Center opened a new cancer-treatment center in North Bergen on Wednesday to serve some of the 4,000 patients each year who are diagnosed with cancer in Hudson County.
read article 



ASCO to Hold Capitol Hill Briefing March 17 to Release State of Cancer Care in America: 2015

(ASCO) Mar 11, 2015 - The State of Cancer Care in America: 2015 report, to be released on March 17 by the American Society of Clinical Oncology (ASCO), chronicles the current realities of the cancer care delivery system in the United States and examines trends in the oncology workforce and practice environment that are affecting patient care and access.
read press release 



Miss. Senate OKs Bill to Stop Higher Co-Pay For Oral Cancer Drug

(The Clarion Ledger [Jackson, MS]) Mar 11, 2015 - The Senate has passed an amended bill to prevent companies from charging a higher co-pay for oral cancer medicine that can be taken at home by patients compared to intravenous cancer drugs traditionally administered in a hospital setting.
read article 



Epizyme Reacquires Global Rights From Eisai for First-in-Class EZH2 Inhibitor EPZ-6438

(NASDAQ) Mar 12, 2015 - Epizyme, Inc. announced today that it has reacquired global rights to its EZH2 program, including EPZ-6438, from its partner Eisai Co. Ltd, or Eisai.
read article 



Ipsen Aims to Boost U.S. Sales With More Workers and New Drugs

(Bloomberg) Mar 12, 2015 - Ipsen is gearing up to introduce Somatuline, a drug it sells for a rare disease, to treat some tumors of the gastrointestinal tract and pancreas.
read article 



After Raising $60M, Kura Oncology Renews Work on Shelved Cancer Drug

(Xconomy San Diego) Mar 12, 2015 - Even after the FDA refused to approve the anti-cancer drug tipifarnib in 2005, some experts could see a tantalizing glimmer of potential for patients with acute myeloid leukemia (AML) and other forms of cancer.
read article 



CDF to Revisit Delisting of Lilly's Alimta

(PharmaTimes [UK]) Mar 12, 2015 - Lilly’s appeal against the Cancer Drugs Fund’s decision to delist its lung cancer drug Alimta (pemetrexed) has been upheld.
read article 



Japan Researchers Screen For Cancer Using Nematodes and Urine

(Wall Street Journal/Japan Real Time blog) Mar 12, 2015 - Researchers in Japan have developed a cancer screening process that uses nematodes and their ability to sniff out cancer-specific odors from patients’ urine samples.
read article (paid registration required)